Literature DB >> 16132749

Extracorporeal shock wave lithotripsy of renal pelvis stones with PCK stonelith lithotripter.

Abdurrahman Ozgür1, N Yalm Iker.   

Abstract

Shock wave lithotripsy (SWL) has made a revolution in the treatment of urolithiasis. It is a safe procedure with a lower morbidity than open surgery or percutaneous nefrolithotomy (PCN). In this article, we analyze our results of SWL with PCK Stonelith-V5 Lithotripter for the renal pelvis localized stones. About 97 patients with radiopaque stone localized in the renal pelvis were treated with PCK lithotripter from January 2001 to March 2003. The study group was divided into two groups according to their stone size. The stone size was < or = 10 mm in the first group and 11-20 mm in the second group. 56(57) patients were male and 41 (43) were female. Age range was 7-68 (mean 44) years. The overall success rates of SWL for the treatment of renal pelvic stones in our study group was 35 and 62.2 for stones 10 mm or less and 11-20 mm, respectively. Since the focal zone is 7.7 x 30 mm, the stones can easily get out of the focal zone area with respiration and as a result, the success rate is decreased. So, general anesthesia can be preferred for the treatment of stones < or =10 mm with the PCK Stonelith Lithotripter.

Entities:  

Mesh:

Year:  2005        PMID: 16132749     DOI: 10.1007/s11255-004-6085-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  8 in total

1.  The first clinical results of "wide-focus and low-pressure" ESWL.

Authors:  W Eisenmenger; X X Du; C Tang; S Zhao; Y Wang; F Rong; D Dai; M Guan; A Qi
Journal:  Ultrasound Med Biol       Date:  2002-06       Impact factor: 2.998

2.  Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association.

Authors:  J W Segura; G M Preminger; D G Assimos; S P Dretler; R I Kahn; J E Lingeman; J N Macaluso
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

3.  Report of the United States cooperative study of extracorporeal shock wave lithotripsy.

Authors:  G W Drach; S Dretler; W Fair; B Finlayson; J Gillenwater; D Griffith; J Lingeman; D Newman
Journal:  J Urol       Date:  1986-06       Impact factor: 7.450

4.  Extracorporeal shock wave lithotripsy: the Methodist Hospital of Indiana experience.

Authors:  J E Lingeman; D Newman; J H Mertz; P G Mosbaugh; R E Steele; R J Kahnoski; T A Coury; J R Woods
Journal:  J Urol       Date:  1986-06       Impact factor: 7.450

5.  Extracorporeal shock wave lithotripsy monotherapy of staghorn calculi with Dornier MFL 5000.

Authors:  N Y Ilker; Y Alican; F Simsek; L N Türkeri; A Akdas
Journal:  J Endourol       Date:  1993-08       Impact factor: 2.942

6.  First clinical experience with extracorporeally induced destruction of kidney stones by shock waves.

Authors:  C Chaussy; E Schmiedt; D Jocham; W Brendel; B Forssmann; V Walther
Journal:  J Urol       Date:  1982-03       Impact factor: 7.450

7.  Prospective randomized comparative study of the effectiveness and safety of electrohydraulic and electromagnetic extracorporeal shock wave lithotriptors.

Authors:  Khaled Z Sheir; Khaled Madbouly; Emad Elsobky
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

8.  Kidney stone removal: percutaneous versus surgical lithotomy.

Authors:  G E Brannen; W H Bush; R J Correa; R P Gibbons; J S Elder
Journal:  J Urol       Date:  1985-01       Impact factor: 7.450

  8 in total
  2 in total

1.  Quantification of the Range of Motion of Kidney and Ureteral Stones During Shockwave Lithotripsy in Conscious Patients.

Authors:  Suzanne R Harrogate; L M Shirley Yick; James C Williams; Robin O Cleveland; Benjamin W Turney
Journal:  J Endourol       Date:  2016-04-01       Impact factor: 2.942

2.  Quantitative assessment of shockwave lithotripsy accuracy and the effect of respiratory motion.

Authors:  Mathew D Sorensen; Michael R Bailey; Anup R Shah; Ryan S Hsi; Marla Paun; Jonathan D Harper
Journal:  J Endourol       Date:  2012-06-13       Impact factor: 2.942

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.